Foghorn Therapeutics releases September 2025 investor presentation without new material disclosures

Foghorn Therapeutics Inc.

Presentation reiterates company focus on unique biology, precision therapeutics, and broad impact.
No new financial, clinical, or strategic data provided in the filing excerpt.
Intended for use in investor meetings; no guidance or material events announced.
Stock ticker FHTX listed on Nasdaq.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.